Madrigal Pharmaceuticals
Develops and commercializes therapeutics for metabolic dysfunction-associated steatohepatitis.
Company facts
- Founded
- 2000
- Employees
- 915
- Headquarters
- United States
- Type
- Public
- Listed
- NASDAQ: MDGL
About
Madrigal Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for metabolic dysfunction-associated steatohepatitis (MASH), formerly NASH. The company focuses on halting or reversing liver fibrosis and resolving MASH before it progresses to cirrhosis, liver failure, or cancer. By leveraging advanced drug discovery platforms and a deep understanding of liver disease biology, Madrigal aims to deliver transformative treatments that address unmet medical needs in metabolic and liver disorders. Its collaborative culture and commitment to scientific rigor position it as a leading force in the liver disease therapeutic arena.